Pfizer 2009 Annual Report Download - page 105

Download and view the complete annual report

Please find page 105 of the 2009 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 110

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110

Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies
QUARTER
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH
2008
Revenues $11,848 $12,129 $11,973 $12,346
Costs and expenses 7,715 8,614 8,872 10,093
Acquisition-related in-process research and development charges 398 156 13 66
Restructuring charges and certain acquisition-related costs 178 569 366 1,562
Income from continuing operations before provision for taxes on
income 3,557 2,790 2,722 625
Provision for taxes on income 763 25 463 394
Income from continuing operations 2,794 2,765 2,259 231
Discontinued operations—net of tax (4) 17 25 40
Net income before allocation to noncontrolling interests 2,790 2,782 2,284 271
Less: Net income attributable to noncontrolling interests 6 6 6 5
Net income attributable to Pfizer Inc. $ 2,784 $ 2,776 $ 2,278 $ 266
Earnings per common share—basic:
Income from continuing operations attributable to Pfizer Inc.
common shareholders $ 0.41 $ 0.41 $ 0.34 $ 0.03
Discontinued operations—net of tax — — — 0.01
Net income attributable to Pfizer Inc. common shareholders $ 0.41 $ 0.41 $ 0.34 $ 0.04
Earnings per common share—diluted:
Income from continuing operations attributable to Pfizer Inc.
common shareholders $ 0.41 $ 0.41 $ 0.33 $ 0.03
Discontinued operations—net of tax — — 0.01 0.01
Net income attributable to Pfizer Inc. common shareholders $ 0.41 $ 0.41 $ 0.34 $ 0.04
Cash dividends paid per common share $ 0.32 $ 0.32 $ 0.32 $ 0.32
Stock prices
High $ 24.24 $ 21.60 $ 20.13 $ 19.39
Low $ 20.19 $ 17.12 $ 17.16 $ 14.26
Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS
amounts may not agree to the total for the year.
Revenues include a reduction of $217 million recorded in the third quarter of 2008 to adjust our prior years’ liabilities for product
returns.
Costs and expenses includes a charge of $2.3 billion recorded in the fourth quarter of 2008 related to the resolution of certain
investigations concerning Bextra and various other products, and charges of $900 million recorded in the third quarter of 2008
associated with the resolution of certain litigation involving our NSAID pain medicines.
Acquisition-related in-process research and development charges primarily includes amounts incurred in connection with our
acquisitions of Serenex, Encysive, CovX, Coley and a number of animal health product lines in Europe from Schering-Plough, as
well as two smaller acquisitions also related to animal health.
2009 Financial Report 103